Blood Test Identifies Those At-Risk Of Alzeimer's Within Three Years

Researchers have discovered and validated a blood test that can predict with greater than 90 percent accuracy if a healthy person will develop mild cognitive impairment or Alzheimer's disease within three years.

Described in the April issue of Nature Medicine, the study heralds the potential for developing treatment strategies for Alzheimer's at an earlier stage, when therapy would be more effective at slowing or preventing onset of symptoms.

The test identifies 10 lipids, or fats, in the blood that predict disease onset. It could be ready for use in clinical studies in as few as two years and, researchers say, other diagnostic uses are possible.

"Our novel blood test offers the potential to identify people at risk for progressive cognitive decline and can change how patients, their families and treating physicians plan for and manage the disorder," said the study's corresponding author Howard J. Federoff, MD, PhD, professor of neurology and executive vice president for health sciences at Georgetown University Medical Center.

There is no cure or effective treatment for Alzheimer's. Worldwide, about 35.6 million individuals have the disease and, according to the World Health Organization, the number will double every 20 years to 115.4 million people with Alzheimer’s by 2050.

Mr Federoff explained there have been many efforts to develop drugs to slow or reverse the progression of Alzheimer’s disease, but all of them have failed. He says one reason may be the drugs were evaluated too late in the disease process.

"The preclinical state of the disease offers a window of opportunity for timely disease-modifying intervention," Mr Federoff said. "Biomarkers such as ours that define this asymptomatic period are critical for successful development and application of these therapeutics."

The study included 525 healthy participants aged 70 and older who gave blood samples upon enrolling and at various points in the study. Over the course of the five-year study, 74 participants met the criteria for either mild Alzheimer’s disease (AD) or a condition known as amnestic mild cognitive impairment (aMCI), in which memory loss is prominent. Of these, 46 were diagnosed upon enrollment and 28 developed aMCI or mild AD during the study.


Related UK National News Stories
Click here for the latest headlines.

06 December 2006
Feline Alzheimer's risk for cats
Ageing cats can develop a feline form of Alzheimer’s disease, a new study has claimed. Researchers at the Universities of Edinburgh, St Andrews, Bristol and California identified a key protein which can build up in the nerve cells of a cat's brain and cause mental deterioration.
21 July 2005
Blood donors warned over possible vCJD carriage
Around 100 people who donated blood to three people who subsequently developed vCJD, have been warned that they may have a greater chance of carrying the agent that causes the disease.
01 October 2010
Kidney Function Linked To Heart And Brain
People with impaired kidney function are at a higher risk of future stroke than people with normal kidney function, new studies have found. The studies, carried out by the British Medical Association, finds that even the earliest stages of chronic kidney disease are linked to a higher risk of coronary heart disease.
15 February 2011
Obesity Is Heart Disease Killer In Its Own Right, Study Shows
Obesity is a killer in its own right, irrespective of other biological or social risk factors traditionally associated with coronary heart disease, suggests research published online in Heart.
08 December 2006
Transfusion risk for vCJD 'substantial'
People given blood transfusions contaminated with the agent that causes variant Creutzfeldt-Jakob Disease (vCJD) are now considered to be at substantial risk.